Lumirubin

Last updated
Lumirubin
(Z)-Lumirubin.svg
(Z)-isomer of lumirubin
Names
IUPAC name
3-[2-[[6-(2-carboxyethyl)-7,11-dimethyl-12-oxo-4,13-diazatricyclo[8.3.0.03,7]trideca-1,3,5,9-tetraen-5-yl]methyl]-5-[(E)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
  • InChI=1S/C33H36N4O6/c1-6-19-16(2)24(36-32(19)43)13-23-17(3)20(7-9-29(38)39)25(34-23)14-27-22(8-10-30(40)41)33(5)12-11-21-18(4)31(42)37-26(21)15-28(33)35-27/h6,11,13,15,18,34H,1,7-10,12,14H2,2-5H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b24-13+
    Key: BYVDUQYJIIPFIB-ZMOGYAJESA-N
  • CC1C2=CCC3(C(=NC(=C3CCC(=O)O)CC4=C(C(=C(N4)/C=C/5\C(=C(C(=O)N5)C=C)C)C)CCC(=O)O)C=C2NC1=O)C
Properties
C33H36N4O6
Molar mass 584.673 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Lumirubin is a structural isomer of bilirubin, which is formed during phototherapy used to treat neonatal jaundice. This polar isomer resulting from the blue-green lights of phototherapy has an active site to albumin, and its effects are considered less toxic than those of bilirubin. [1] [2] [3] Lumirubin is excreted into bile or urine. ZZ, ZE, EE and EZ are the four structural isomers of bilirubin. ZZ is the stable, more insoluble form. Other forms are relatively soluble and are known as lumirubins. Phototherapy converts the ZZ form into lumirubins. Monoglucuronylated lumirubins are easily excreted. [4]

Related Research Articles

Jaundice Abnormal pigmentation symptom for disease of the liver

Jaundice, also known as icterus, is a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels. Jaundice in adults is typically a sign indicating the presence of underlying diseases involving abnormal heme metabolism, liver dysfunction, or biliary-tract obstruction. The prevalence of jaundice in adults is rare, while jaundice in babies is common, with an estimated 80% affected during their first week of life. The most commonly associated symptoms of jaundice are itchiness, pale feces, and dark urine.

Bilirubin Chemical compound

Bilirubin (BR) is a red-orange compound that occurs in the normal catabolic pathway that breaks down heme in vertebrates. This catabolism is a necessary process in the body's clearance of waste products that arise from the destruction of aged or abnormal red blood cells. In the first step of bilirubin synthesis, the heme molecule is stripped from the hemoglobin molecule. Heme then passes through various processes of porphyrin catabolism, which will vary according to the region of the body in which the breakdown occurs. For example, the molecules excreted in the urine differ from those in the feces. The production of biliverdin from heme is the first major step in the catabolic pathway, after which the enzyme biliverdin reductase performs the second step, producing bilirubin from biliverdin.

Kernicterus Medical condition

Kernicterus is a bilirubin-induced brain dysfunction. The term was coined in 1904 by Schmorl. Bilirubin is a naturally occurring substance in the body of humans and many other animals, but it is neurotoxic when its concentration in the blood is too high, a condition known as hyperbilirubinemia. Hyperbilirubinemia may cause bilirubin to accumulate in the grey matter of the central nervous system, potentially causing irreversible neurological damage. Depending on the level of exposure, the effects range from clinically unnoticeable to severe brain damage and even death.

Gilberts syndrome Medical condition

Gilbert syndrome (GS) is a syndrome in which the liver of affected individuals processes bilirubin more slowly than the majority. It confers significant health benefits. Many people never have symptoms. Occasionally jaundice may occur.

Hemolytic anemia Medical condition

Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels or elsewhere in the human body (extravascular). This most commonly occurs within the spleen, but also can occur in the reticuloendothelial system or mechanically. Hemolytic anemia accounts for 5% of all existing anemias. It has numerous possible consequences, ranging from general symptoms to life-threatening systemic effects. The general classification of hemolytic anemia is either intrinsic or extrinsic. Treatment depends on the type and cause of the hemolytic anemia.

Light therapy Treatment for seasonal affective disorder or exposure of the skin to specific wavelengths of light

Light therapy—or phototherapy, classically referred to as heliotherapy—is a method recognized by scientific medicine for the treatment of various diseases. It includes exposure to outdoor daylight or specific indoor artificial light sources.

Athetosis Medical condition

Athetosis is a symptom characterized by slow, involuntary, convoluted, writhing movements of the fingers, hands, toes, and feet and in some cases, arms, legs, neck and tongue. Movements typical of athetosis are sometimes called athetoid movements. Lesions to the brain are most often the direct cause of the symptoms, particularly to the corpus striatum. This symptom does not occur alone and is often accompanied by the symptoms of cerebral palsy, as it is often a result of this physical disability. Treatments for athetosis are not very effective, and in most cases are simply aimed at managing the uncontrollable movement, rather than the cause itself.

Neonatal jaundice Medical condition

Neonatal jaundice is a yellowish discoloration of the white part of the eyes and skin in a newborn baby due to high bilirubin levels. Other symptoms may include excess sleepiness or poor feeding. Complications may include seizures, cerebral palsy, or kernicterus.

Dubin–Johnson syndrome Medical condition

Dubin–Johnson syndrome is a rare, autosomal recessive, benign disorder that causes an isolated increase of conjugated bilirubin in the serum. Classically, the condition causes a black liver due to the deposition of a pigment similar to melanin. This condition is associated with a defect in the ability of hepatocytes to secrete conjugated bilirubin into the bile, and is similar to Rotor syndrome. It is usually asymptomatic, but may be diagnosed in early infancy based on laboratory tests. No treatment is usually needed.

Crigler–Najjar syndrome Rare inherited disorder affecting the metabolism of bilirubin

Crigler–Najjar syndrome is a rare inherited disorder affecting the metabolism of bilirubin, a chemical formed from the breakdown of the heme in red blood cells. The disorder results in a form of nonhemolytic jaundice, which results in high levels of unconjugated bilirubin and often leads to brain damage in infants. The disorder is inherited in an autosomal recessive manner. The annual incidence is estimated at 1 in 1 000 000.

In ABO hemolytic disease of the newborn maternal IgG antibodies with specificity for the ABO blood group system pass through the placenta to the fetal circulation where they can cause hemolysis of fetal red blood cells which can lead to fetal anemia and HDN. In contrast to Rh disease, about half of the cases of ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further pregnancies.

Rotor syndrome Medical condition

Rotor syndrome is a rare cause of mixed direct (conjugated) and indirect (unconjugated) hyperbilirubinemia, relatively benign, autosomal recessive bilirubin disorder characterized by non-hemolytic jaundice due to the chronic elevation of predominantly conjugated bilirubin.

UDP glucuronosyltransferase 1 family, polypeptide A1

UDP-glucuronosyltransferase 1-1 also known as UGT-1A is an enzyme that in humans is encoded by the UGT1A1 gene.

Biliblanket

A biliblanket is a portable phototherapy device used to treat neonatal jaundice (hyperbilirubinemia). BiliBlanket is a trademark of General Electric's Datex-Ohmeda subsidiary, but its name has become the generic, colloquial term for a range of similar products and the term used in the medical professions. The name "biliblanket" combines the words bilirubin and blanket. The baby is placed in direct contact with the pad. This device is also known as home phototherapy system, bilirubin blanket, or bidirectional fiber-optic phototherapy blanket.

Pyknocytosis is a hematologic state characterized by the presence of pyknocytes in the blood. Pyknocytes are red blood cells that appear distorted, irregular and small with abnormal projections and would typically be identified by a medical scientist and verified by a pathologist on a peripheral blood smear.

Neonates are defined as babies up to 28 days after birth. Most extremely preterm babies require at least one red cell transfusion; this is partly due to the amount of blood removed with blood samples compared to the baby's total blood volume and partly due to anemia of prematurity. Most transfusions are given as small volume top-up transfusions to increase the baby's hemoglobin above a certain pre-defined level, or because the baby is unwell due to the anemia. Possible side-effects of anemia in babies can be poor growth, lethargy and episodes of apnea. Exchange blood transfusion is used to treat a rapidly rising bilirubin that does not respond to treatment with phototherapy or intravenous immunoglobulin. This is usually due to hemolytic disease of the newborn, but may also be due to other causes, e.g., G6PD deficiency.

Bilirubin glucuronide Chemical compound

Bilirubin glucuronide is a water-soluble reaction intermediate over the process of conjugation of indirect bilirubin. Bilirubin glucuronide itself belongs to the category of conjugated bilirubin along with bilirubin di-glucuronide. However, only the latter one is primarily excreted into the bile in the normal setting.

Hemolytic jaundice, also known as prehepatic jaundice, is a type of jaundice arising from hemolysis or excessive destruction of red blood cells, when the byproduct bilirubin is not excreted by the hepatic cells quickly enough. Unless the patient is concurrently affected by hepatic dysfunctions or is experiencing hepatocellular damage, the liver does not contribute to this type of jaundice.

References

  1. Dvořák, Aleš; Pospíšilová, Kateřina; Žížalová, Kateřina; Capková, Nikola; Muchová, Lucie; Vecka, Marek; Vrzáčková, Nikola; Křížová, Jana; Zelenka, Jaroslav; Vítek, Libor (2021). "The Effects of Bilirubin and Lumirubin on Metabolic and Oxidative Stress Markers". Frontiers in Pharmacology. 12: 567001. doi:10.3389/fphar.2021.567001. ISSN   1663-9812. PMC   7969661 . PMID   33746746.
  2. Jašprová, Jana; Dvořák, Aleš; Vecka, Marek; Leníček, Martin; Lacina, Ondřej; Valášková, Petra; Zapadlo, Miloš; Plavka, Richard; Klán, Petr; Vítek, Libor (2020-03-10). "A novel accurate LC-MS/MS method for quantitative determination of Z-lumirubin". Scientific Reports. 10 (1): 4411. doi:10.1038/s41598-020-61280-z. ISSN   2045-2322.
  3. Jasprova, Jana; Matteo Dal Ben; Eleonora Vianello; Iryna Goncharova; Marie Urbanova; Karolina Vyroubalova; Silvia Gazzin; Claudio Tiribelli; Martin Sticha; Marcela Cerna; Libor Vitek (1 February 2016). "The Biological Effects of Bilirubin Photoisomers". PLoS ONE. 11 (2): e0148126. doi: 10.1371/journal.pone.0148126 .
  4. Ennever JF, Sobel M, McDonagh AF, Speck WT (July 1984). "Phototherapy for neonatal jaundice: in vitro comparison of light sources". Pediatr. Res. 18 (7): 667–70. doi: 10.1203/00006450-198407000-00021 . PMID   6540860.